|
|
| | Cifurtilimab Basic information |
| Product Name: | Cifurtilimab | | Synonyms: | Cifurtilimab;Research Grade Cifurtilimab;Cifurtilimab (anti-CD40) | | CAS: | 1629760-27-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cifurtilimab Structure]() |
| | Cifurtilimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Cifurtilimab Usage And Synthesis |
| Uses | Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities[1][2]. | | in vivo | In preclinical mouse models, Cifurtilimab combined with chemotherapeutic agents to drive robust anti-tumor activity[2]. | | References | [1] Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.
[2] Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020. |
| | Cifurtilimab Preparation Products And Raw materials |
|